AnaptysBio reports FY2022 net loss $128.7M; cash $584.2M; initiates Phase 2b trials for rosnilimab and ANB032

ANAPTYSBIO, INC

2022-FY EPS reported -$4.57 revenue$10,287,000

Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.
Cash, cash equivalents and investments totaled $584.2M as of Dec 31, 2022; cash runway through year-end 2026 reiterated.
Initiating global Phase 2b trial for rosnilimab (PD-1 agonist) in RA in Q3 2023; second Phase 2 trial in another indication by year-end 2023.
Initiating global Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis in Q2 2023; top-line data expected year-end 2024.
Board authorized $50M stock repurchase plan in January 2023, expiring Dec 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANAPTYSBIO, INC reported financial results for the three months and year ended December 31, 2022.

Period: the three months and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 1, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.